
Professor Andrew Steer - Director, Infection and Immunity, Murdoch Children’s Research Institute. Professor John Carroll - Director, Monash Biomedicine Discovery Institute. Professor Terry Nolan - Head, Vaccine and Immunisation Research Group, Doherty Institute at University of Melbourne, and MCRI. Professor Doug Hilton - Director, Walter and Eliza Hall Institute of Medical Research. Professor Brendan Crabb - Director, Burnet Institute. Professor William Charman - Sir John Monash Distinguished Professor, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Dr Barney Graham - Deputy Director, Vaccine Research Center, US National Institutes of Health. Professor Sharon Lewin - Director, Doherty Institute. Dr Amanda Caples - Victoria’s Lead Scientist and Chair of the Group. The Scientific Advisory Group works in consultation with mRNA Victoria, supporting the development of the mRNA ecosystem and research in Victoria. MRNA Victoria is advised by a Scientific Advisory Group made up of world-leading experts from the medical research sector. MRNA Victoria’s Scientific Advisory Group International Engagement and Investment Opportunities. Development of Australia’s first mRNA Vaccine. mRNA Victoria’s Industry Advisory Panel. mRNA Victoria’s Scientific Advisory Group.
Through grants, international market entry support, facilitating and entering into research agreements and partnerships, mRNA Victoria delivers programs to support the development and commercialisation of mRNA research. Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability. MRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.